• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by Daiichi Sankyo

    < Previous 1 2 Next >
    Datopotamab Deruxtecan Plus Durvalumab Showed Promising Clinical Activity in the First-Line Advanced Non-Small Cell Lung Cancer Setting in TROPION-Lung04 Phase 1b Trial
    From Daiichi Sankyo
    Via Business Wire
    Ifinatamab Deruxtecan Continues to Demonstrate Durable Responses in Patients with Advanced Small Cell Lung Cancer in Early Trial
    From Daiichi Sankyo
    Via Business Wire
    Patritumab Deruxtecan Demonstrated Clinically Meaningful and Durable Responses in Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer in HERTHENA-Lung01 Phase 2 Trial
    From Daiichi Sankyo
    Via Business Wire
    DS-3939 Enters Clinical Development in Patients Across Several Types of Advanced Solid Cancers
    From Daiichi Sankyo
    Via Business Wire
    ENHERTU® Granted Two Breakthrough Therapy Designations in U.S. for Patients Across Multiple HER2 Expressing Cancers
    From Daiichi Sankyo
    Via Business Wire
    Daiichi Sankyo Highlights Progress in Creating New Standards of Care for Patients with Lung Cancer with Data Across DXd ADC Portfolio at WCLC
    From Daiichi Sankyo
    Via Business Wire
    VANFLYTA® Now Available in U.S. for Patients with Newly Diagnosed FLT3-ITD Positive AML
    From Daiichi Sankyo
    Via Business Wire
    ENHERTU® Demonstrated Clinically Meaningful Progression-Free Survival and Overall Survival Across Multiple HER2 Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase 2 Trial
    From Daiichi Sankyo
    Via Business Wire
    VANFLYTA® First FLT3 Inhibitor Approved in the U.S. Specifically for Patients with Newly Diagnosed FLT3-ITD Positive AML
    From Daiichi Sankyo
    Via Business Wire
    Datopotamab Deruxtecan Met Dual Primary Endpoint of Progression-Free Survival in Patients with Advanced Non Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial
    From Daiichi Sankyo
    Via Business Wire
    Datopotamab Deruxtecan Combinations Showed Encouraging Tumor Responses in Patients with Advanced Non-Small Cell Lung Cancer in TROPION-Lung02 Phase 1b trial
    From Daiichi Sankyo
    Via Business Wire
    ENHERTU® Demonstrated Clinically Meaningful and Durable Responses in Patients Across Multiple HER2 Expressing Advanced Solid Tumors
    From Daiichi Sankyo
    Via Business Wire
    Daiichi Sankyo Showcases Latest Research Towards Creating New Standards of Care for Patients with Cancer with Data at ASCO and EHA
    From Daiichi Sankyo
    Via Business Wire
    Quizartinib NDA Review for Patients with Newly Diagnosed FLT3-ITD Positive AML Extended by FDA
    From Daiichi Sankyo
    Via Business Wire
    Patritumab Deruxtecan Continues to Show Encouraging Clinical Activity in Distinct Patient Populations with Metastatic Lung and Breast Cancer in Updated Results of Two Early Trials
    From Daiichi Sankyo
    Via Business Wire
    ENHERTU® Showed Clinically Meaningful and Durable Responses Across Multiple HER2 Expressing Tumor Types in DESTINY-PanTumor02 Phase 2 Trial
    From Daiichi Sankyo
    Via Business Wire
    TURALIO® New Dosing Regimen Now Available in the U.S. for Certain Patients with Tenosynovial Giant Cell Tumor
    From Daiichi Sankyo
    Via Business Wire
    TROPION-Lung07 Phase 3 Trial Initiated to Evaluate Datopotamab Deruxtecan in Combination with Pembrolizumab in Patients with Previously Untreated Metastatic Non-Small Cell Lung Cancer
    From Daiichi Sankyo
    Via Business Wire
    Datopotamab Deruxtecan Showed Promising Responses as Monotherapy and in Combination with Durvalumab in Patients with Metastatic Triple Negative Breast Cancer in Two Early Trials
    From Daiichi Sankyo
    Via Business Wire
    Datopotamab Deruxtecan Showed Encouraging and Durable Efficacy in Patients with Heavily Pretreated HR Positive, HER2 Low or Negative Metastatic Breast Cancer
    From Daiichi Sankyo
    Via Business Wire
    ENHERTU® Achieved Statistically Significant Overall Survival Reducing the Risk of Death by 36% Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast Cancer in DESTINY-Breast03
    From Daiichi Sankyo
    Via Business Wire
    Data Across Daiichi Sankyo DXd ADC Portfolio at 2022 SABCS Demonstrates Bold Progress in Advancing Treatment for Patients with Breast Cancer
    From Daiichi Sankyo
    Via Business Wire
    Quizartinib Granted Priority Review in the U.S. for Patients with Newly Diagnosed FLT3-ITD Positive Acute Myeloid Leukemia
    From Daiichi Sankyo
    Via Business Wire
    ENHERTU® Continues to Demonstrate Clinically Meaningful Tumor Response in Patients with HER2 Mutant Metastatic Non-Small Cell Lung Cancer
    From Daiichi Sankyo
    Via Business Wire
    DS-7300 Continues to Show Promising Durable Response in Patients with Several Types of Advanced Cancer
    From Daiichi Sankyo
    Via Business Wire
    Daiichi Sankyo Continues to Make Bold Strides in Oncology Across DXd ADC Portfolio at 2022 ESMO
    From Daiichi Sankyo
    Via Business Wire
    ENHERTU® Significantly Delayed Disease Progression in DESTINY-Breast02 Phase 3 Trial Versus Physician’s Choice of Treatment in Patients with HER2 Positive Metastatic Breast Cancer
    From Daiichi Sankyo
    Via Business Wire
    Arbitrator Rules in Favor of Daiichi Sankyo in Dispute with Seagen
    From Daiichi Sankyo
    Via Business Wire
    ENHERTU® Approved in the U.S. as the First HER2 Directed Therapy for Patients with Previously Treated HER2 Mutant Metastatic Non-Small Cell Lung Cancer
    From Daiichi Sankyo
    Via Business Wire
    Datopotamab Deruxtecan-Based Combinations Show Promising Clinical Activity in Patients with Advanced Non-Small Cell Lung Cancer
    From Daiichi Sankyo
    Via Business Wire
    < Previous 1 2 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.